List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3200787/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology, 2018, 73, 596-609.	1.9	237
2	Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder. European Urology, 2007, 52, 1204-1212.	1.9	222
3	A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. European Urology, 2016, 69, 94-102.	1.9	201
4	Urology practice during the COVID-19 pandemic. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 369-375.	3.9	195
5	180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH Study. European Urology, 2014, 65, 931-942.	1.9	189
6	Defining overactive bladder: Epidemiology and burden of disease. Urology, 2004, 64, 2-6.	1.0	156
7	Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Reviews Urology, 2016, 13, 613-626.	3.8	155
8	Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?. European Urology, 2020, 78, 786-811.	1.9	150
9	Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. European Urology, 2015, 68, 418-425.	1.9	147
10	A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. Journal of Urology, 2015, 193, 570-578.	0.4	117
11	Clinical pathways for urology patients during the COVID-19 pandemic. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 376-383.	3.9	80
12	Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?. BMC Urology, 2015, 15, 96.	1.4	63
13	Metabolic Syndrome and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Enlargement: A Possible Link to Storage Symptoms. Urology, 2014, 84, 1181-1187.	1.0	50
14	Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1–pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors?. European Urology, 2015, 67, 943-951.	1.9	45
15	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Therapeutic Advances in Urology, 2017, 9, 137-154.	2.0	43
16	Central obesity is predictive of persistent storage lower urinary tract symptoms ( <scp>LUTS</scp> ) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU International, 2015, 116, 271-277.	2.5	37
17	Impact of the COVIDâ€19 pandemic on urological practice in emergency departments in Italy. BJU International, 2020, 126, 245-247.	2.5	36
18	A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU International, 2015, 116, 853-861.	2.5	35

ANDREA TUBARO

#	Article	IF	CITATIONS
19	Overactive bladder: epidemiology and social impact. Current Opinion in Obstetrics and Gynecology, 2005, 17, 507-511.	2.0	34
20	Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU International, 2016, 117, E29-35.	2.5	33
21	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. Clinical Genitourinary Cancer, 2019, 17, 402-407.	1.9	33
22	The Relation of Lower Urinary Tract Symptoms with Life-Style Factors and Objective Measures of Benign Prostatic Enlargement and Obstruction: An Italian Survey. European Urology, 2004, 45, 767-772.	1.9	32
23	Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urology, 2017, 17, 22.	1.4	32
24	Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients' care – a systematic review. BMC Urology, 2018, 18, 62.	1.4	28
25	Risk of Virus Contamination Through Surgical Smoke During Minimally Invasive Surgery: A Systematic Review of the Literature on a Neglected Issue Revived in the COVID-19 Pandemic Era. European Urology Focus, 2020, 6, 1058-1069.	3.1	28
26	The management of overactive bladder. Current Opinion in Urology, 2015, 25, 305-310.	1.8	28
27	The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. European Journal of Surgical Oncology, 2018, 44, 835-839.	1.0	27
28	The use of laser as a therapeutic modality as compared to TURP for the small prostate â‰ <b>¤</b> 0 mL: a collaborative review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 569-575.	3.9	26
29	Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer, 2016, 16, 407.	2.6	24
30	Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre crossâ€sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU International, 2016, 117, 867-873.	2.5	23
31	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	2.2	23
32	Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology, 2016, 96, 165-170.	1.0	21
33	Do Young Patients with Renal Cell Carcinoma Feature a Distinct Outcome after Surgery? A Comparative Analysis of Patient Age Based on the Multinational CORONA Database. Journal of Urology, 2014, 191, 310-315.	0.4	20
34	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq0 0 0 rg	BT1/Øverlo	ock200 Tf 50 1
35	Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Neurourology and Urodynamics, 2016, 35, 278-282.	1.5	19

<sup>36</sup>The diagnosis of benign prostatic obstruction: Development of a clinical nomogram. Neurourology<br/>and Urodynamics, 2016, 35, 235-240.1.519

#	Article	IF	CITATIONS
37	An update on prostate biopsy in the era of magnetic resonance imaging. Minerva Urology and Nephrology, 2018, 70, 264-274.	2.5	19
38	Bladder weight and detrusor thickness as parameters of progression of benign prostatic hyperplasia. Current Opinion in Urology, 2010, 20, 37-42.	1.8	18
39	Metabolic Syndrome, Obesity, and Radical Cystectomy Complications: A Clavien Classification System-Based Analysis. Clinical Genitourinary Cancer, 2014, 12, 384-393.	1.9	18
40	The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery. Current Urology Reports, 2016, 17, 61.	2.2	18
41	Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics, 2021, 10, 373.	3.7	18
42	The Electromagnetic Detection of Prostatic Cancer: Evaluation of Diagnostic Accuracy. Urology, 2008, 72, 340-344.	1.0	17
43	Patients With Prostatic Inflammation Undergoing Transurethral Prostatic Resection Have a Larger Early Improvement of Storage Symptoms. Urology, 2015, 86, 359-367.	1.0	17
44	Castration-resistance prostate cancer: what is in the pipeline?. Minerva Urology and Nephrology, 2018, 70, 22-41.	2.5	17
45	Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 347-360.	3.9	17
46	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. Frontiers in Surgery, 2020, 7, 563006.	1.4	17
47	Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer and Prostatic Diseases, 2018, 21, 287-292.	3.9	16
48	Bladder stone management: an update. Minerva Urology and Nephrology, 2018, 70, 53-65.	2.5	15
49	GreenLight Photoselective Vaporization of the Prostate: One Laser for Different Prostate Sizes. Journal of Endourology, 2020, 34, 54-62.	2.1	15
50	Complications and quality of life of ileal conduit, orthotopic neobladder and ureterocutaneostomy: systematic review of reports using the Clavien-Dindo Classification. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 408-419.	3.9	15
51	Ultrasound imaging of the pelvic floor: Where are we going?. Neurourology and Urodynamics, 2011, 30, 729-734.	1.5	14
52	Tamsulosin or Silodosin Adjuvant Treatment Is Ineffective in Improving Shockwave Lithotripsy Outcome: A Short-Term Follow-Up Randomized, Placebo-Controlled Study. Journal of Endourology, 2016, 30, 817-821.	2.1	14
53	Young Academic Urologists' benign prostatic obstruction nomogram predicts clinical outcome in patients treated with transurethral resection of prostate: an Italian cohort study. Minerva Urology and Nephrology, 2018, 70, 211-217.	2.5	14
54	Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. Urology, 2018, 121, 147-152.	1.0	14

#	Article	IF	CITATIONS
55	Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer and Prostatic Diseases, 2018, 21, 438-445.	3.9	14
56	The role of bladder wall thickness in the evaluation of detrusor underactivity: Development of a clinical nomogram. Neurourology and Urodynamics, 2020, 39, 1115-1123.	1.5	14
57	The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2013, 8, 142-149.	0.5	13
58	Quality of Life and Sexual Health in the Aging of PCa Survivors. International Journal of Endocrinology, 2014, 2014, 1-16.	1.5	13
59	External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 364.e1-364.e7.	1.6	13
60	Variations of Nighttime and Daytime Bladder Capacity in Patients with Nocturia: Implication for Diagnosis and Treatment. Journal of Urology, 2019, 201, 962-966.	0.4	13
61	Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget, 2017, 8, 50904-50910.	1.8	13
62	Cigarette smoking is not associated with prostate cancer diagnosis and aggressiveness: a cross sectional Italian study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 598-605.	3.9	13
63	Early Treatment of Benign Prostatic Hyperplasia. Drugs and Aging, 2003, 20, 185-195.	2.7	12
64	The Evolving Picture of Lower Urinary Tract Symptom Management. European Urology, 2015, 67, 271-272.	1.9	12
65	The Diagnosis of Benign Prostatic Obstruction: Validation of the Young Academic Urologist Clinical Nomogram. Urology, 2015, 86, 1032-1036.	1.0	12
66	The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 2015, 18, 376-386.	0.3	12
67	The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late?. Minerva Urology and Nephrology, 2017, 69, 242-252.	2.5	12
68	Green light vaporization of the prostate: is it an adult technique?. Minerva Urology and Nephrology, 2017, 69, 109-118.	2.5	12
69	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. Journal of Clinical Medicine, 2019, 8, 1126.	2.4	12
70	Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 622-628.	3.9	12
71	Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 80-84.	1.6	11
72	Erectile Dysfunction and Lower Urinary Tract Symptoms. Current Urology Reports, 2018, 19, 61.	2.2	11

#	Article	IF	CITATIONS
73	Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 570-578.	3.9	10
74	Retroperitoneoscopy in urology: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 9-16.	3.9	10
75	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the) Tj ETQq1 2020, 72, 595-604.	1 0.784314 3.9	rgBT/Overlac
76	Reduction of Prostate-specific Antigen After Tamsulosin Treatment in Patients With Elevated Prostate-specific Antigen and Lower Urinary Tract Symptoms Associated With Low Incidence of Prostate Cancer at Biopsy. Urology, 2010, 76, 436-441.	1.0	9
77	Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?. Current Urology Reports, 2017, 18, 72.	2.2	9
78	New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urology and Nephrology, 2017, 69, 119-132.	2.5	9
79	Repeat prostateâ€specific antigen ( <scp>PSA</scp> ) test before prostate biopsy: a 20% decrease in <scp>PSA</scp> values is associated with a reduced risk of cancer and particularly of highâ€grade cancer. BJU International, 2018, 122, 83-88.	2.5	9
80	Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis. World Journal of Urology, 2018, 36, 91-97.	2.2	9
81	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). Urology, 2019, 129, 139-145.	1.0	9
82	Radical penectomy, a compromise for life: results from the PECAD study. Translational Andrology and Urology, 2020, 9, 1306-1313.	1.4	9
83	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. European Urology Oncology, 2021, 4, 49-55.	5.4	9
84	Laparoscopic simple prostatectomy: a large single-center prospective cohort study. Minerva Urology and Nephrology, 2021, 73, 107-113.	2.5	9
85	Development of a nomogram predicting the probability of stone free rate in patients with ureteral stones eligible for semi-rigid primary laser uretero-litothripsy. World Journal of Urology, 2021, 39, 4267-4274.	2.2	9
86	The urothelium, the urinary microbioma and men LUTS: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 712-722.	3.9	9
87	Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life1Matthias May and Luca Cindolo have equally contributed to first authorship.2Sabine Brookman-May and Petros Sountoulides have equally contributed to last authorship Urologic Oncology: Seminars and Original Investigations, 2014, 32,	1.6	8
88	Metabolic Syndrome Does Not Increase the Risk of Ejaculatory Dysfunction in Patients With Lower Urinary Tract Symptoms and Benign Prostatic Enlargement: An Italian Single-center Cohort Study. Urology, 2017, 105, 85-90.	1.0	8
89	Detrusor overactivity increases bladder wall thickness in male patients: A urodynamic multicenter cohort study. Neurourology and Urodynamics, 2017, 36, 1616-1621.	1.5	8
90	Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review. Current Urology Reports, 2018, 19, 70.	2.2	8

#	Article	IF	CITATIONS
91	The EORTC quality of life questionnaire predicts early and long-term incontinence in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 1006-1013.	1.6	8
92	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	2.5	8
93	Initial Experience and Evaluation of a Nomogram for Outcome Prediction in Management of Medium-sized (1–2 cm) Kidney Stones. European Urology Focus, 2022, 8, 276-282.	3.1	8
94	Ejaculation disorders in prostate surgery. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 549-550.	3.9	8
95	Investigation of benign prostatic hyperplasia. Current Opinion in Urology, 2003, 13, 17-22.	1.8	7
96	Non-invasive ultrasound measurements in male patients with LUTS and benign prostatic obstruction: implication for diagnosis and treatment. Minerva Urology and Nephrology, 2017, 69, 220-233.	2.5	7
97	External validation of Imamura nomogram as a tool to predict preoperatively laser semi-rigid ureterolithotripsy outcomes. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 531-536.	3.9	7
98	The effect of bladder outlet obstruction treatment on ultrasound-determined bladder wall thickness. Reviews in Urology, 2005, 7 Suppl 6, S35-42.	0.9	7
99	Impairment of autophagy may represent the molecular mechanism behind the relationship between obesity and inflammation in patients with BPH and LUTS. Minerva Urology and Nephrology, 2021, 73, 631-637.	2.5	7
100	Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: A prospective single cohort study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 28.e27-28.e31.	1.6	6
101	Basic methods for the assessment of health-related quality of life in uro-oncological patients. Minerva Urology and Nephrology, 2017, 69, 409-420.	2.5	6
102	Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. Neurourology and Urodynamics, 2018, 37, 904-915.	1.5	6
103	Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology, 2020, 38, 1757-1764.	2.2	6
104	Transperineal Interstitial Laser Ablation of the Prostate, A Novel Option for Minimally Invasive Treatment of Benign Prostatic Obstruction. European Urology, 2021, 80, 673-674.	1.9	6
105	Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation. European Journal of Surgical Oncology, 2021, 47, 2640-2645.	1.0	6
106	Night shift workers refer higher urinary symptoms with an impairment quality of life: a single cohort study. Minerva Urology and Nephrology, 2020, , .	2.5	6
107	Re: Safety and Feasibility of the Prostatic Urethral Lift: A Novel, Minimally Invasive Treatment for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). European Urology, 2011, 60, 1120-1121.	1.9	5
108	Innovations in medical and surgical treatment. Nature Reviews Urology, 2015, 12, 76-78.	3.8	5

#	Article	IF	CITATIONS
109	Re: Association Between the Amount of Vaginal Mesh Used with Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 2019, 75, 196-197.	1.9	5
110	External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. World Journal of Urology, 2020, 38, 2555-2561.	2.2	5
111	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. European Urology Focus, 2021, 7, 432-439.	3.1	5
112	Smoking reduces PSA accuracy for detection of prostate cancer: results from an Italian cross-sectional study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 583-589.	3.9	5
113	Dutasteride addâ€on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alphaâ€adrenergic antagonist monotherapy: A single center prospective study. Neurourology and Urodynamics, 2017, 36, 2096-2100.	1.5	4
114	Medical treatment for benign prostatic hyperplasia: Where do we stand?. Urologia, 2019, 86, 115-121.	0.7	4
115	Moderate-to-high cardiovascular risk is associated with increased lower urinary tract storage symptoms in patients with benign prostatic enlargement. Minerva Urology and Nephrology, 2018, 70, 340-346.	2.5	4
116	The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 729-736.	3.9	4
117	Transurethral needle ablation of the prostate. Current Opinion in Urology, 2007, 17, 7-11.	1.8	3
118	Re: Christian Gratzke, Alexander Bachmann, Aurelien Descazeaud, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2015;67:1099–109 European Urology, 2015, 68, e15.	1.9	3
119	Complex renal masses: partial or no partial nephrectomy?. Annals of Translational Medicine, 2019, 7, S312-S312.	1.7	3
120	Is our current understanding and management of nocturia allowing improved care? International Consultation on Incontinenceâ€Research Society 2018. Neurourology and Urodynamics, 2019, 38, S127-S133.	1.5	3
121	Obesity and Prostate Cancer: The Tip of a High Mountain Still to Be Conquered. Journal of Clinical Medicine, 2020, 9, 2070.	2.4	3
122	Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study. Minerva Urology and Nephrology, 2019, , .	2.5	3
123	Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2021, , .	2.5	3
124	Post-Operative Acute Urinary Retention After Greenlight Laser. Analysis Of Risk Factors from A Multicentric Database. Urology Journal, 2021, , .	0.4	3
125	Serum levels of 17-Î <sup>2</sup> -estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e9-35.e13.	1.6	2
126	Grey Zone: Urinary Incontinence. European Urology Focus, 2016, 2, 337-338.	3.1	2

#	ARTICLE	IF	CITATIONS
127	Re: Glorgio Ivan Russo, Carmen Scandura, Marina Di Mauro, et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.01.002.	3.1	2
128	Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. European Urology Focus, 2021, 7, 178-185.	3.1	2
129	Contemporary management of benign uretero-enteric strictures after cystectomy: a systematic review. Minerva Urology and Nephrology, 2022, 73, .	2.5	2
130	Re: Association Between Metabolic Syndrome and Severity of Lower Urinary Tract Symptoms: An Observational Study in a 4666 European Men Cohort. European Urology, 2015, 67, 973-974.	1.9	1
131	Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy. European Urology, 2018, 73, 980-981.	1.9	1
132	Expert Opinion on Three Clinical Cases with a Common Urgent Problem: Urge Urinary Incontinence. Case Reports in Urology, 2018, 2018, 1-6.	0.3	1
133	Exercise to prevent lower urinary tract symptoms: myth and reality. BJU International, 2018, 122, 170-170.	2.5	1
134	Re: Mini Percutaneous Nephrolithotomy Is a Noninferior Modality to Standard Percutaneous Nephrolithotomy for the Management of 20–40 mm Renal Calculi: A Multicenter Randomized Controlled Trial. European Urology, 2021, 80, 114-115.	1.9	1
135	Ultrasound prostate parameters as predictors of successful trial without catheter after acute urinary retention in patients ongoing medical treatment for benign prostatic hyperplasia: a prospective multicenter study. Minerva Urology and Nephrology, 2021, 73, 625-630.	2.5	1
136	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	2.5	1
137	Re: Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology, 2014, 65, 1220-1221.	1.9	Ο
138	Editorial Comment from Dr Presicce <i>etÂal</i> . to Emerging links between nonâ€neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. International Journal of Urology, 2015, 22, 992-992.	1.0	0
139	Can a patient reported outcome be adequate without assessing quality of life in lower urinary tract dysfunction?. Neurourology and Urodynamics, 2017, 36, 943-948.	1.5	Ο
140	Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory) Tj ETQq0 0 0 r	gBT /Qverlo	ock <sub>0</sub> 10 Tf 50 2
141	Urinary Urgency: A Symptom In Need Of A Cure. Research and Reports in Urology, 2019, Volume 11, 327-331.	1.0	0
142	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
143	A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. Journal of Urology, 2021, 205, 1145-1152.	0.4	Ο
144	Digital rectal examination and prostate biopsy at the time of COVID-19 outbreak: are there risks of	2.5	0

contamination for the urologist?. Minerva Urology and Nephrology, 2021, 73, 268-269. 144 ISRS 0 2.5

#	Article	IF	CITATIONS
145	Urology practice during the COVID-19 vaccination campaign. Urologia, 2021, 88, 039156032110163.	0.7	0
146	Male Lower Urinary Tract Symptoms and Benign Prostatic Obstruction: What Do Patients Want?. European Urology, 2021, 79, 810-811.	1.9	0
147	Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort. Minerva Urology and Nephrology, 2020, , .	2.5	ο